RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn's Disease

World News: . []

The independent Data and Safety Monitoring Board DSMB reviewed safety and efficacy data of which RedHill remains blinded from the first 222 subjects who have completed week 26 assessments in the Phase III MAP US study To date over 300 of the...

More news and information about RedHill Biopharma Ltd.

Published By:

Thomson Reuters: 13:00 GMT Monday 31st July 2017

Published: .

Search for other references to "redhill" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us